Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-23
    E.g., 2018-10-23

Archive Search

Pages

14652 items
5:55 PM, Oct 18, 2018  |  BC Innovations | Translation in Brief

Sorting out exosomes

A team of Japanese researchers have identified UBL3 as a new therapeutic target for cancers and neurodegenerative diseases that spread via the exosome-based intercellular communication system. The ubiquitin system sorts proteins for cellular export via...
5:40 PM, Oct 18, 2018  |  BC Innovations | Emerging Company Profile

Altheia: Proliferating PD-L1

Rather than blocking PD-L1 to treat cancer, Altheia Science s.r.l. is increasing expression of PD-L1 via a cell therapy to promote immune tolerance in autoimmune diseases, starting with Type I diabetes and multiple sclerosis. Altheia...
5:36 PM, Oct 18, 2018  |  BC Innovations | Tools & Techniques

Allogeneic CARs on the horizon

With the first generation of autologous, personalized CAR T cell therapies on the market, the field is turning to allogeneic technologies to provide better scale and lower costs. But drug makers are learning that as...
4:44 PM, Oct 18, 2018  |  BC Innovations | Targets & Mechanisms

Volkow: why pain and addiction will go personalized

While addiction still carries a social stigma, neuroscience research not only supports the view that it is a disease, but is starting to paint a more nuanced picture of the variety of mechanistic pathways involved....
11:45 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Dermatology

INDICATION: Scars/wrinkles Patient sample and mouse studies suggest inhibiting CXCL12 could help treat scars. In injured skin samples from scar patients, CXCL12 levels were higher in patients aged 40 years or younger with thick scars than...
11:45 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Musculoskeletal

INDICATION: Muscular dystrophy Patient sample, cell culture and mouse studies suggest inhibiting CB1 could help treat Duchenne muscular dystrophy (DMD). In quadriceps tissue samples from pediatric DMD patients, CB1 expression levels were higher than in...
11:44 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Cell culture and mouse studies suggest inhibiting CASP1 could help treat AD. In primary human neurons overexpressing APP, a tool compound CASP1 inhibitor decreased axon degeneration compared with no treatment. In a...
11:43 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Musculoskeletal; autoimmune disease

INDICATION: Osteoporosis; arthritis Mouse studies suggest inhibiting miR-182 could help treat osteoporosis and arthritis. In a mouse model of estrogen deficiency-induced osteoporosis, myeloid lineage osteoclast precursor-specific knockout of miR-182 or chitosan nanoparticles loaded with an antisense...
11:43 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Brain cancer Patient sample and mouse studies suggest inhibiting Notch 1 could help treat metastatic medulloblastoma. In primary tumor samples from medulloblastoma patients, levels of Notch 1 were higher in patients with metastases than in...
11:41 AM, Oct 18, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest the selective GABA re-uptake inhibitor tiagabine could help treat neonatal hypoxic brain injury. In a neonatal mouse model of hypoxia-induced brain injury, tiagabine decreased the percentage of missteps, a measure of...

Pages